Table 1.
Characteristics of the study participants, by group
| HIV-positive | HIV-negative | p value | |||
|---|---|---|---|---|---|
| Noncontroller (without cART) (n = 32) | cART recipient (n = 26) | HIV-controller (without cART)(n = 36) | (n = 35) | ||
| Age (years)a | 35 (25.25–40) | 49.5 (40.75–53.75) | 44 (39.5–48.5) | 49 (41–53) | 0.022b |
| Sex (%) | |||||
| Men | 75 | 77 | 68 | 64 | 0.399b |
| Women | 25 | 23 | 32 | 36 | |
| T cell count, cells/μLa | |||||
| CD4+ | 554 (478–713.5) | 570 (435–760) | 680 (574–1132) | – | 0.002 |
| CD8+ | 865 (736–1148) | 694 (433–910) | 1031 (622–1470) | – | 0.016 |
| Viral loada HIV-1 RNA copies/mL | 26,956 (1512.75–54,579.50) | < 20 | 28.5 (< 20–446.75) | – | < 0.001 |
| Duration after diagnosis (years)a | 0.16 (0.08–1) | 12 (4.75–16) | 14 (7.5–19) | – | < 0.001 |
cART combination antiretroviral therapy, NA not applicable, NS not significant
aData are median (interquartile range, IQR)
bData denote results of comparisons between HIV-positive vs. HIV-negative